Pancreatica.org is a Clearinghouse for Current, Credible, and Comprehensive Research and Information for Pancreatic Cancer Patients

Breakthrough Treatment Results for advanced Pancreatic Cancer

Preliminary findings of a Phase III U.S. clinical trial with the orally administered FDA-designated “orphan drug” daraxonrasib, which acts as a selective RAS genetic (mutation) inhibitor (present in more than 90% of those with pancreatic cancer) were reported out by the clinical oncology Revolution Medicines company in a press release in April 2026.

The results were highly encouraging in that those in the study (all with previously treated advanced ductal adenocarcinoma of the pancreas) who received just the oral daraxonrasib alone (daily, 300 mg) doubled their overall survival duration to 13.2 months as compared to those who otherwise received standard chemotherapy (6.7 months).

Side effects were observed to be mild to moderate consisting primarily of a rash, mouth sores, and/or GI signs & symptoms.

Subsequently, the U.S. FDA has granted Expanded Access Protocol (EAP) status under “safe to proceed” guidelines for daraxonrasib for similar patients who test positive for the RAS mutation, upon request by a treating physician.  More information on this clinical trial will soon be forthcoming.

Further research will be required to confirm these results. But for now, these findings are seen as not only a new approach to treatment, but importantly as a conceptual breakthrough utilizing known biology to fashion a more precise remedy. As such, the promise could lead to other important treatment progress.